{"product_id":"sphchina-swot-analysis","title":"Shanghai Pharma SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eShanghai Pharma blends a dominant domestic distribution network and robust R\u0026amp;D pipeline with strategic M\u0026amp;A that fuel revenue growth, yet faces pricing pressure, regulatory scrutiny, and fierce competition from generics and global biotechs—opportunities lie in specialty drugs and international expansion. Discover the full SWOT analysis to access a research-backed, editable report and Excel tools that turn these insights into actionable strategy for investors and executives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVertical Integration Across the Entire Value Chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShanghai Pharmaceuticals Holding Co., Ltd. runs a fully integrated model—R\u0026amp;D, manufacturing, distribution, and retail—covering drug discovery to point-of-sale, which in 2024 supported RMB 110.5 billion revenue and gross margin ~26.8% (FY2024).\u003c\/p\u003e\n\u003cp\u003eThis end-to-end control tightens quality, cuts costs (manufacturing and distribution synergies reduced COGS by ~120–180 bps in 2023–24), and speeds market response, outpacing niche players.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Position in Pharmaceutical Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025 Shanghai Pharma is the second-largest medical distributor in China, covering all 31 provinces and holding roughly a 15–18% market share in national drug distribution.\u003c\/p\u003e\n\u003cp\u003eIts distribution arm drives over 90% of group revenue, and in 2024–2025 served more than 30,000 medical institutions, including a broad mix of tier 1–3 hospitals and pharmacies.\u003c\/p\u003e\n\u003cp\u003eThis nationwide network makes Shanghai Pharma a critical pillar of China’s healthcare infrastructure, enabling scale, bargaining power, and steady cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Financial Performance and Liquidity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpshanghai pharmaceuticals pharma showed net profit growth of nearly in q1 driven by higher margins and distribution. operating cash flow exceeded for the same period supplying acquisitions r without tapping equity markets. company maintained a debt-to-capital ratio around supporting investment while keeping leverage moderate. this liquidity solvency mix underpins its capacity large-scale strategic moves.\u003e\n\u003c\/pshanghai\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Focus on R\u0026amp;D and Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eShanghai Pharma pivoted to innovation, raising R\u0026amp;D to ~10% of manufacturing revenue by 2025 and targeting proprietary drugs over low-margin generics.\u003c\/p\u003e\n\u003cp\u003eThe group runs 60+ new drug candidates across preclinical to late-stage trials, concentrating on oncology, immunology, and cardiovascular therapies to capture high-growth markets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D ~10% of manufacturing revenue (2025)\u003c\/li\u003e\n\u003cli\u003e60+ drug candidates across clinical stages\u003c\/li\u003e\n\u003cli\u003eFocus: oncology, immunology, cardiovascular\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Brand Heritage and Retail Presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpwith a retail chain of over pharmacies including the guoda brand shanghai pharma operates powerful direct-to-consumer platform that drove revenue rmb billion in about group sales.\u003e\n\u003cpits portfolio of long-standing tcm brands with combined annual sales near rmb billion in sustains high consumer trust and cross-generational recognition.\u003e\n\u003cpthe mix of modern pharmacy networks and heritage tcm gives shanghai pharma unique positioning across urban older demographics boosting same-store sales growth in\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2,000+ pharmacies (Guoda flagship)\u003c\/li\u003e\n\u003cli\u003eRMB 49.8B retail sales 2024\u003c\/li\u003e\n\u003cli\u003eRMB 8.6B TCM brand sales 2024\u003c\/li\u003e\n\u003cli\u003e6.2% same-store sales growth 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthe\u003e\u003c\/pits\u003e\u003c\/pwith\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated R\u0026amp;D-to-Retail Fuels RMB110.5B Revenue, 60+ Drug Pipeline \u0026amp; Solid Margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntegrated R\u0026amp;D-to-retail model drove RMB 110.5B revenue, ~26.8% gross margin (FY2024); distribution ~90% revenue, 15–18% national share (2025); retail 2,000+ stores, RMB 49.8B retail sales (2024); R\u0026amp;D ≈10% of manufacturing revenue with 60+ drug candidates; Q1–Q3 2025 net profit +27%, operating cash flow \u0026gt; net profit, debt-to-capital ~0.40.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (FY2024)\u003c\/td\u003e\n\u003ctd\u003eRMB 110.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e26.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail sales (2024)\u003c\/td\u003e\n\u003ctd\u003eRMB 49.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e~10% manuf. rev (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug candidates\u003c\/td\u003e\n\u003ctd\u003e60+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket share (distribution)\u003c\/td\u003e\n\u003ctd\u003e15–18% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeverage\u003c\/td\u003e\n\u003ctd\u003eDebt-to-capital ~0.40\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Shanghai Pharma, highlighting its strengths, weaknesses, opportunities, and threats to assess competitive position and strategic prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT snapshot of Shanghai Pharma for rapid strategic alignment and clear executive briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Revenue Concentration in Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite an integrated healthcare model, Shanghai Pharma reported distribution revenue at 91.3% of total sales in 2025, leaving the group highly exposed to low-margin logistics (gross margin ~6–8% in 2024–25). This concentration amplifies earnings volatility: a 5% drop in distribution volumes would shave roughly 4.6% off consolidated revenue, and shifts in government procurement or supply-chain disruptions could disproportionately hit net profit given narrow distribution EBITDA margins (~2–3%).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLower Profit Margins in Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe manufacturing arm saw a 4.2% year-on-year revenue decline in H1 2025, hit by fierce domestic competition and national drug-pricing reforms that cut average selling prices by ~12% for key generics.\u003c\/p\u003e\n\u003cp\u003eShanghai Pharma is shifting to innovative drugs, yet ~58% of FY2024 sales still came from generics, leaving margins squeezed; gross margin for manufacturing fell to 21.5% in FY2024 versus 32% at major global peers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity in Integrating Large-Scale Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShanghai Pharma’s aggressive M\u0026amp;A push, including the 2021 acquisition of a controlling stake in Shanghai Hutchison Pharmaceuticals (deal value ~RMB 8.8 billion), raises integration risks as it manages 200+ subsidiaries and diverse units; consolidating operations demands heavy managerial bandwidth and drove 2023 impairment charges of RMB 1.2 billion, showing how missed synergies can harm margins and dilute shareholder value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSlower Internationalization Compared to Global Peers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eShanghai Pharma remains a domestic leader but had only about 8% of FY2024 revenue from overseas operations versus ~40% for top global peers like Pfizer and Roche; its international sales were CNY 6.4bn of total CNY 80bn revenue in 2024.\u003c\/p\u003e\n\u003cp\u003eIts innovative pipeline faces early-stage regulatory navigation in the U.S. and EU, with no FDA approvals by end-2024 and only 2 EMA\/foreign trial filings, slowing market access for high-margin drugs.\u003c\/p\u003e\n\u003cp\u003eLimited global presence concentrates risk in China as regulatory tightening cut industry growth to 2.5% in 2024; this restricts revenue diversification and currency-hedged earnings.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOverseas revenue: ~8% (CNY 6.4bn) in 2024\u003c\/li\u003e\n\u003cli\u003eNo FDA approvals by end-2024; 2 EMA\/foreign filings\u003c\/li\u003e\n\u003cli\u003ePeers’ overseas share: ~40%\u003c\/li\u003e\n\u003cli\u003eChina pharma growth: 2.5% in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Operational Costs and Workforce Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eWith nearly 50,000 employees, Shanghai Pharma carries heavy personnel and admin costs that pressured 2024 operating margin (reported 8.2%), especially across 31 provinces where fixed overhead rises.\u003c\/p\u003e\n\u003cp\u003eLarge-scale operations amplify vulnerability in downturns; a 5% revenue decline would cut incremental profit sharply given high fixed SGA expenses.\u003c\/p\u003e\n\u003cp\u003eSTEM and digital talent shortages push hiring costs up—market salary premiums rose ~12% for biotech\/digital roles in 2024—raising R\u0026amp;D pivot expenses and retention risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~50,000 employees → high payroll and SGA\u003c\/li\u003e\n\u003cli\u003eOperations across 31 provinces → elevated fixed overhead\u003c\/li\u003e\n\u003cli\u003e2024 operating margin ~8.2% → sensitive to revenue dips\u003c\/li\u003e\n\u003cli\u003eSTEM\/digital salaries +12% in 2024 → higher R\u0026amp;D costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow‑margin distribution and stalled manufacturing squeeze profits; weak global reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy reliance on low‑margin distribution (91.3% of sales; dist. GM ~6–8% in 2024–25) and slow manufacturing recovery (–4.2% H1 2025) squeeze profits; generics still ~58% of sales, manufacturing GM 21.5% in 2024. M\u0026amp;A integration strains (RMB 1.2bn impairments 2023), limited overseas revenue (~CNY 6.4bn, 8% in 2024), no FDA approvals by end‑2024, high fixed SGA with ~50,000 staff.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution share\u003c\/td\u003e\n\u003ctd\u003e91.3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDist. gross margin\u003c\/td\u003e\n\u003ctd\u003e6–8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing GM (2024)\u003c\/td\u003e\n\u003ctd\u003e21.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverseas rev (2024)\u003c\/td\u003e\n\u003ctd\u003eCNY 6.4bn (8%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eShanghai Pharma SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; purchase unlocks the entire in-depth version. You’re viewing a live preview of the actual SWOT analysis file, and the complete, editable document becomes available after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752859873657,"sku":"sphchina-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/sphchina-swot-analysis.png?v=1772246705","url":"https:\/\/matrixbcg.com\/products\/sphchina-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}